195 related articles for article (PubMed ID: 25405754)
21. Plasma microRNAs as potential new biomarkers for early detection of early gastric cancer.
Zhu XL; Ren LF; Wang HP; Bai ZT; Zhang L; Meng WB; Zhu KX; Ding FH; Miao L; Yan J; Wang YP; Liu YQ; Zhou WC; Li X
World J Gastroenterol; 2019 Apr; 25(13):1580-1591. PubMed ID: 30983818
[TBL] [Abstract][Full Text] [Related]
22. Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer.
Zanutto S; Pizzamiglio S; Ghilotti M; Bertan C; Ravagnani F; Perrone F; Leo E; Pilotti S; Verderio P; Gariboldi M; Pierotti MA
Br J Cancer; 2014 Feb; 110(4):1001-7. PubMed ID: 24423916
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of microRNAs-29a, 92a and 145 in colorectal carcinoma as candidate diagnostic markers: An Egyptian pilot study.
Ramzy I; Hasaballah M; Marzaban R; Shaker O; Soliman ZA
Clin Res Hepatol Gastroenterol; 2015 Sep; 39(4):508-15. PubMed ID: 25736690
[TBL] [Abstract][Full Text] [Related]
24. Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.
Fan L; Qi H; Teng J; Su B; Chen H; Wang C; Xia Q
Tumour Biol; 2016 Jun; 37(6):7777-84. PubMed ID: 26695145
[TBL] [Abstract][Full Text] [Related]
25. Plasma microRNA-103, microRNA-107, and microRNA-194 levels are not biomarkers for human diffuse gastric cancer.
Oze I; Shimada S; Nagasaki H; Akiyama Y; Watanabe M; Yatabe Y; Matsuo K; Yuasa Y
J Cancer Res Clin Oncol; 2017 Mar; 143(3):551-554. PubMed ID: 27909811
[TBL] [Abstract][Full Text] [Related]
26. Circulating miR-21, miR-29a, and miR-126 are associated with premature death risk due to cancer and cardiovascular disease: the JACC Study.
Yamada H; Suzuki K; Fujii R; Kawado M; Hashimoto S; Watanabe Y; Iso H; Fujino Y; Wakai K; Tamakoshi A
Sci Rep; 2021 Mar; 11(1):5298. PubMed ID: 33674633
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of serum miR-103 predicts unfavorable prognosis in patients with colorectal cancer.
Wang DS; Zhong B; Zhang MS; Gao Y
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4518-4523. PubMed ID: 30058684
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic performance of microRNA-29a for colorectal cancer: a meta-analysis.
Zhi ML; Liu ZJ; Yi XY; Zhang LJ; Bao YX
Genet Mol Res; 2015 Dec; 14(4):18018-25. PubMed ID: 26782449
[TBL] [Abstract][Full Text] [Related]
29. Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer.
Zhang J; Raju GS; Chang DW; Lin SH; Chen Z; Wu X
Cancer; 2018 Feb; 124(4):785-796. PubMed ID: 29112225
[TBL] [Abstract][Full Text] [Related]
30. Role of miRNA-210, miRNA-21 and miRNA-126 as diagnostic biomarkers in colorectal carcinoma: impact of HIF-1α-VEGF signaling pathway.
Sabry D; El-Deek SEM; Maher M; El-Baz MAH; El-Bader HM; Amer E; Hassan EA; Fathy W; El-Deek HEM
Mol Cell Biochem; 2019 Apr; 454(1-2):177-189. PubMed ID: 30357530
[TBL] [Abstract][Full Text] [Related]
31. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
[TBL] [Abstract][Full Text] [Related]
32. Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection.
Matamala N; Vargas MT; González-Cámpora R; Miñambres R; Arias JI; Menéndez P; Andrés-León E; Gómez-López G; Yanowsky K; Calvete-Candenas J; Inglada-Pérez L; Martínez-Delgado B; Benítez J
Clin Chem; 2015 Aug; 61(8):1098-106. PubMed ID: 26056355
[TBL] [Abstract][Full Text] [Related]
33. The diagnostic efficacy of circulating miRNAs in monitoring the early development of colitis-induced colorectal cancer.
El-Daly SM; Morsy SM; Medhat D; El-Bana MA; Latif YA; Omara EA; Awadallah JR; Gamal-Eldeen AM
J Cell Biochem; 2019 Oct; 120(10):16668-16680. PubMed ID: 31095784
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Methodologies to Detect Low Levels of Hemolysis in Serum for Accurate Assessment of Serum microRNAs.
Shah JS; Soon PS; Marsh DJ
PLoS One; 2016; 11(4):e0153200. PubMed ID: 27054342
[TBL] [Abstract][Full Text] [Related]
35. Examining plasma microRNA markers for colorectal cancer at different stages.
Sun Y; Liu Y; Cogdell D; Calin GA; Sun B; Kopetz S; Hamilton SR; Zhang W
Oncotarget; 2016 Mar; 7(10):11434-49. PubMed ID: 26863633
[TBL] [Abstract][Full Text] [Related]
36. Potential circulating miRNA signature for early detection of NSCLC.
Arab A; Karimipoor M; Irani S; Kiani A; Zeinali S; Tafsiri E; Sheikhy K
Cancer Genet; 2017 Oct; 216-217():150-158. PubMed ID: 29025589
[TBL] [Abstract][Full Text] [Related]
37. Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients.
Elemeery MN; Badr AN; Mohamed MA; Ghareeb DA
World J Gastroenterol; 2017 Jun; 23(21):3864-3875. PubMed ID: 28638226
[TBL] [Abstract][Full Text] [Related]
38. A Pilot Study of Circulating MicroRNA-125b as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer.
Zhu T; Gao W; Chen X; Zhang Y; Wu M; Zhang P; Wang S
Int J Gynecol Cancer; 2017 Jan; 27(1):3-10. PubMed ID: 27636713
[TBL] [Abstract][Full Text] [Related]
39. Circulating miRNA-21 and miRNA-23a Expression Signature as Potential Biomarkers for Early Detection of Non-Small-Cell Lung Cancer.
Hetta HF; Zahran AM; Shafik EA; El-Mahdy RI; Mohamed NA; Nabil EE; Esmaeel HM; Alkady OA; Elkady A; Mohareb DA; Hosni A; Mostafa MM; Elkady A
Microrna; 2019; 8(3):206-215. PubMed ID: 30652656
[TBL] [Abstract][Full Text] [Related]
40. Analysis of circulating microRNA: preanalytical and analytical challenges.
McDonald JS; Milosevic D; Reddi HV; Grebe SK; Algeciras-Schimnich A
Clin Chem; 2011 Jun; 57(6):833-40. PubMed ID: 21487102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
